In the U.S., the FDA is approving more biosimilars and patients are benefitting from these new medicines. Access to these safe, effective treatments offers patients improved health outcomes. For more information, visit www.biosimilarscouncil.org.

A biosimilar is a biologic medicine that is highly similar to a brand biologic medicine. The FDA requires biosimilars to undergo rigorous testing and review, ensuring they are safe and effective. As a result, biosimilars offer the same safety and efficacy as their brand-name counterparts, but at a lower cost to patients and the health system. Companies that manufacture biosimilars are committed to providing safe, effective products.

Biosimilars are: Safe, effective, more affordable and offer improved patient access.

More than 20 biosimilars have now been approved by the U.S. Food and Drug Administration (FDA). Biosimilars have the potential to increase patient access to lower-cost treatment and reduce the price of brand-name biologics.

To learn more about barriers to patient access, view our white paper series Failure to Launch: Part 1 and Part 2.